Clinical trial · Observational
Glycemic Fluctuations in Newly Diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome Subjects
Characteristics of Glycemic Fluctuations in Newly Diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome Subjects
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Glucose fluctuations present not only in patients with diabetes mellitus but also in subjects with normal glucose tolerance or impaired glucose regulation. People with Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome are at risk of impaired glucose metabolism. Glycemic variability is poorly studied in the nondiabetic individuals. The aim of the study is to investigate the characteristics of glucose fluctuations in the newly diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome individuals.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pituitary Adenoma | Pituitary Neuroendocrine Tumor | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| continuous glucose monitoring | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Continuous glucose profiles of mean data of 24-hour continuous glucose monitoring by the CGMS Gold
- timeFrame
- 3 days
- description
- The monitoring results consisted of one curve and 5 parameters
Secondary outcomes (4)
- measure
- The mean amplitude of glycemic excursion of newly diagnosed GH adenoma patients
- timeFrame
- 3 days
- description
- The mean amplitude of glycemic excursion of newly diagnosed GH adenoma patients during the 3 days monitored by CGMS Gold
- measure
- The mean amplitude of glycemic excursion of newly diagnosed Cushing Syndrome patients during the 3 days monitored by CGMS Gold
- timeFrame
- 3 days
- description
- The mean amplitude of glycemic excursion of newly diagnosed Cushing Syndrome patients during the 3 days monitored by CGMS Gold
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * •newly diagnosed GH-releasing pituitary adenoma * •newly diagnosed Cushing Syndrome Exclusion Criteria: * •history of diabetes mellitus and being treated with drugs * •being treated with drugs which affect glucose metabolism in the lately 3 months * •with other hormones affecting glucose metabolism secreted abnormally by pituitary * •serious comorbidity like malignant tumour, severe hepatosis or nephropathy, serious hypertension(blood pressure\> 180/110mmhg) * •pregnant or breastfeeding women * •patients allergic to patches or metal
References
Publications (0)
Data not yet available